Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-12-21
2000-08-01
Reamer, James H.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3144
Patent
active
060967579
ABSTRACT:
Methods are provided for treating proliferative diseases, especially cancers, comprising administering (1) a farnesyl protein transferase inhibitor in conjunction with (2) an antineoplastic agent and/or radiation therapy.
REFERENCES:
patent: 5340828 (1994-08-01), Graham et al.
patent: 5416091 (1995-05-01), King
patent: 5661152 (1997-08-01), Bishop et al.
patent: 5719148 (1998-02-01), Bishop et al.
patent: 5801175 (1998-09-01), Alfonso et al.
patent: 5874442 (1999-02-01), Doll et al.
Gibbs, vol. 65, 1-4, Apr. 5, 1991.
Sepp-Lorenzo et al., Cancer Research 55, 5302-5309, Nov. 15, 1995.
Moasser, et al., Proc. Natl. Acad. Sci. USA, vol. 95, pp. 1369-1374, Feb. 1998.
Travis, Science, vol. 260, pp. 1877-1878, Jun. 25, 1993.
Kohl, et al., Nature Medicine, vol. 1, pp. 792-797, No. 8, Aug. 1995.
Kohl, et al., Proc. Natl. Acad. Sci. USA, vol. 91, pp. 9141-9145, Sep. 1994.
Levitzki, Current Opinion In Cell Biology vol. 8, pp. 239-244, 1996.
Bernhard, et al., Cancer Research 56, 1727-1730, Apr. 15, 1996.
DeVita, et al., "Cancer, Principles & Practice of Oncology," 5.sup.th Ed. pp.445-446, Lippencott-Raven (Phila., 1997).
Liu, et al., Cancer Research 58, 4947-4956, Nov. 1, 1998.
Nagasu, et al., Cancer Research 55, 5310-5314, Nov. 1995.
"SCH66336 Plus Gemictabine For All Advanced Malignancies" (print-out from Internet, 1999).
Shi, et al., "Enhanced efficacy of the farnesly protein transferase inhibitor SCH66336 in combination with paclitaxel", Proceedings of the American Association For Cancer Research Annual Meeting, 1999 (Abstract No. 3457).
Schlitzer, "Hemmstoffe der Farnesyltransferase: Ein neuer Ansatz zur Entwicklung potentieller Krebstherapeutika," Pharmazie in Unserer Zeit, vol. 27, No. 6, Nov. 1998 pp. 278-288.
Omer et al.: "CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents," Trends in Pharmacological Sciences, vol. 18, No. 11, Nov. 1, 1997, pp. 437-445.
Miller et al., Increased radioresistance of Ejras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation, (Abstract from Int. J. Cancer, 53 (2): 302-7 (Jan. 21, 1993).
Hausheer et al., "Ab initio quantum mechanica l and x-ray crystallographic studies of gemcitabine and 2'-deoxycytosine", Comput. Chem., 20(4), 459-467, 1996.
Bishop Walter R.
Catino Joseph J.
Cutler David L.
Doll Ronald J.
Ganguly Ashit
Gould James M.
Jeanette Henry C.
Reamer James H.
Schering Corporation
LandOfFree
Method for treating proliferative diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating proliferative diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating proliferative diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-664322